Mitochondrial dysfunction represses HIF-1α protein synthesis through AMPK activation in human hepatoma HepG2 cells. 2013

Chia-Chi Hsu, and Chun-Hui Wang, and Ling-Chia Wu, and Cheng-Yuan Hsia, and Chin-Wen Chi, and Pen-Hui Yin, and Chun-Ju Chang, and Ming-Ta Sung, and Yau-Huei Wei, and Shing-Hwa Lu, and Hsin-Chen Lee
Department and Institute of Pharmacology, National Yang-Ming University, Taiwan.

BACKGROUND Hypoxia-inducible factor-1α (HIF-1α) is an important transcription factor that modulates cellular responses to hypoxia and also plays critical roles in cancer progression. Recently, somatic mutations and decreased copy number of mitochondrial DNA (mtDNA) were detected in hepatocellular carcinoma (HCC). These mutations were shown to have the potential to cause mitochondrial dysfunction. However, the effects and mechanisms of mitochondrial dysfunction on HIF-1α function are not fully understood. This study aims to explore the underlying mechanism by which mitochondrial dysfunction regulates HIF-1α expression. METHODS Human hepatoma HepG2 cells were treated with various mitochondrial respiration inhibitors and an uncoupler, respectively, and the mRNA and protein expressions as well as transactivation activity of HIF-1α were determined. The role of AMP-activated protein kinase (AMPK) was further analyzed by compound C and AMPK knock-down. RESULTS Treatments of mitochondrial inhibitors and an uncoupler respectively reduced both the protein level and transactivation activity of HIF-1α in HepG2 cells under normoxia or hypoxia. The mitochondrial dysfunction-repressed HIF-1α protein synthesis was associated with decreased phosphorylations of p70(S6K) and 4E-BP-1. Moreover, mitochondrial dysfunction decreased intracellular ATP content and elevated the phosphorylation of AMPK. Treatments with compound C, an AMPK inhibitor, and knock-down of AMPK partially rescued the mitochondrial dysfunction-repressed HIF-1α expression. CONCLUSIONS Mitochondrial dysfunctions resulted in reduced HIF-1α protein synthesis through AMPK-dependent manner in HepG2 cells. CONCLUSIONS Our results provided a mechanism for communication from mitochondria to the nucleus through AMPK-HIF-1α. Mitochondrial function is important for HIF-1α expression in cancer progression.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008928 Mitochondria Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Each mitochondrion is surrounded by a double limiting membrane. The inner membrane is highly invaginated, and its projections are called cristae. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP. They contain distinctive RIBOSOMES, transfer RNAs (RNA, TRANSFER); AMINO ACYL T RNA SYNTHETASES; and elongation and termination factors. Mitochondria depend upon genes within the nucleus of the cells in which they reside for many essential messenger RNAs (RNA, MESSENGER). Mitochondria are believed to have arisen from aerobic bacteria that established a symbiotic relationship with primitive protoeukaryotes. (King & Stansfield, A Dictionary of Genetics, 4th ed) Mitochondrial Contraction,Mitochondrion,Contraction, Mitochondrial,Contractions, Mitochondrial,Mitochondrial Contractions
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000263 Adenylate Kinase An enzyme that catalyzes the phosphorylation of AMP to ADP in the presence of ATP or inorganic triphosphate. EC 2.7.4.3. Myokinase,AMP Kinase,ATP-AMP Phosphotransferase,ATP-AMP Transphosphorylase,Adenylokinase,ATP AMP Phosphotransferase,ATP AMP Transphosphorylase,Kinase, AMP,Kinase, Adenylate,Phosphotransferase, ATP-AMP,Transphosphorylase, ATP-AMP
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D051795 Hypoxia-Inducible Factor 1, alpha Subunit Hypoxia-inducible factor 1, alpha subunit is a basic helix-loop-helix transcription factor that is regulated by OXYGEN availability and is targeted for degradation by VHL TUMOR SUPPRESSOR PROTEIN. Hypoxia Inducible Factor 1, alpha Subunit
D056945 Hep G2 Cells A human liver tumor cell line used to study a variety of liver-specific metabolic functions. Cell Line, Hep G2,Cell Line, Hepatoblastoma G2,Hep G2 Cell Line,HepG2 Cells,Hepatoblastoma G2 Cell Line,Cell, Hep G2,Cell, HepG2,Cells, Hep G2,Cells, HepG2,Hep G2 Cell,HepG2 Cell
D060888 Real-Time Polymerase Chain Reaction Methods used for detecting the amplified DNA products from the polymerase chain reaction as they accumulate instead of at the end of the reaction. Kinetic Polymerase Chain Reaction,Quantitative Real-Time PCR,Quantitative Real-Time Polymerase Chain Reaction,Real-Time PCR,PCR, Quantitative Real-Time,PCR, Real-Time,PCRs, Quantitative Real-Time,PCRs, Real-Time,Quantitative Real Time PCR,Quantitative Real Time Polymerase Chain Reaction,Quantitative Real-Time PCRs,Real Time PCR,Real Time Polymerase Chain Reaction,Real-Time PCR, Quantitative,Real-Time PCRs,Real-Time PCRs, Quantitative

Related Publications

Chia-Chi Hsu, and Chun-Hui Wang, and Ling-Chia Wu, and Cheng-Yuan Hsia, and Chin-Wen Chi, and Pen-Hui Yin, and Chun-Ju Chang, and Ming-Ta Sung, and Yau-Huei Wei, and Shing-Hwa Lu, and Hsin-Chen Lee
January 2023, Frontiers in physiology,
Chia-Chi Hsu, and Chun-Hui Wang, and Ling-Chia Wu, and Cheng-Yuan Hsia, and Chin-Wen Chi, and Pen-Hui Yin, and Chun-Ju Chang, and Ming-Ta Sung, and Yau-Huei Wei, and Shing-Hwa Lu, and Hsin-Chen Lee
January 2012, International journal of molecular sciences,
Chia-Chi Hsu, and Chun-Hui Wang, and Ling-Chia Wu, and Cheng-Yuan Hsia, and Chin-Wen Chi, and Pen-Hui Yin, and Chun-Ju Chang, and Ming-Ta Sung, and Yau-Huei Wei, and Shing-Hwa Lu, and Hsin-Chen Lee
September 2009, Molecular nutrition & food research,
Chia-Chi Hsu, and Chun-Hui Wang, and Ling-Chia Wu, and Cheng-Yuan Hsia, and Chin-Wen Chi, and Pen-Hui Yin, and Chun-Ju Chang, and Ming-Ta Sung, and Yau-Huei Wei, and Shing-Hwa Lu, and Hsin-Chen Lee
June 2009, Journal of agricultural and food chemistry,
Chia-Chi Hsu, and Chun-Hui Wang, and Ling-Chia Wu, and Cheng-Yuan Hsia, and Chin-Wen Chi, and Pen-Hui Yin, and Chun-Ju Chang, and Ming-Ta Sung, and Yau-Huei Wei, and Shing-Hwa Lu, and Hsin-Chen Lee
August 2016, Cancer letters,
Chia-Chi Hsu, and Chun-Hui Wang, and Ling-Chia Wu, and Cheng-Yuan Hsia, and Chin-Wen Chi, and Pen-Hui Yin, and Chun-Ju Chang, and Ming-Ta Sung, and Yau-Huei Wei, and Shing-Hwa Lu, and Hsin-Chen Lee
March 2011, European journal of pharmacology,
Chia-Chi Hsu, and Chun-Hui Wang, and Ling-Chia Wu, and Cheng-Yuan Hsia, and Chin-Wen Chi, and Pen-Hui Yin, and Chun-Ju Chang, and Ming-Ta Sung, and Yau-Huei Wei, and Shing-Hwa Lu, and Hsin-Chen Lee
June 2011, Molecular cancer therapeutics,
Chia-Chi Hsu, and Chun-Hui Wang, and Ling-Chia Wu, and Cheng-Yuan Hsia, and Chin-Wen Chi, and Pen-Hui Yin, and Chun-Ju Chang, and Ming-Ta Sung, and Yau-Huei Wei, and Shing-Hwa Lu, and Hsin-Chen Lee
June 2005, Free radical biology & medicine,
Chia-Chi Hsu, and Chun-Hui Wang, and Ling-Chia Wu, and Cheng-Yuan Hsia, and Chin-Wen Chi, and Pen-Hui Yin, and Chun-Ju Chang, and Ming-Ta Sung, and Yau-Huei Wei, and Shing-Hwa Lu, and Hsin-Chen Lee
October 2011, European journal of pharmacology,
Chia-Chi Hsu, and Chun-Hui Wang, and Ling-Chia Wu, and Cheng-Yuan Hsia, and Chin-Wen Chi, and Pen-Hui Yin, and Chun-Ju Chang, and Ming-Ta Sung, and Yau-Huei Wei, and Shing-Hwa Lu, and Hsin-Chen Lee
October 2016, International journal of oncology,
Copied contents to your clipboard!